Spots Global Cancer Trial Database for immunochemotherapy
Every month we try and update this database with for immunochemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant SBRT in Localized Advanced HNSCC | NCT06306846 | Head and Neck S... | SBRT+immunochem... Immunochemother... cetuximab+immun... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Neoadjuvant SBRT in Localized Advanced HNSCC | NCT06306846 | Head and Neck S... | SBRT+immunochem... Immunochemother... cetuximab+immun... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | NCT06070961 | Follicular Lymp... | Cellular immuni... Humoral immunit... Cellular immuni... Humoral immunit... Diphtheria toxi... Tetanus toxoid-... T-cell populati... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) | NCT02782845 | Non-Hodgkin's L... | Chemotherapy Immunochemother... Pegfilgrastim | 18 Years - 65 Years | Hoffmann-La Roche | |
| Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | NCT06383780 | Nasopharyngeal ... | GP combined wit... TPC combined wi... | 18 Years - | Sun Yat-sen University | |
| Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC | NCT05549037 | Non-small Cell ... | Pembrolizumab, ... | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | NCT00147901 | B-cell Chronic ... | FCCam | 18 Years - | German CLL Study Group | |
| Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | NCT00147901 | B-cell Chronic ... | FCCam | 18 Years - | German CLL Study Group | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | NCT01458730 | Central Nervous... | Immunochemother... | 18 Years - 75 Years | University of Aarhus | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | NCT06383780 | Nasopharyngeal ... | GP combined wit... TPC combined wi... | 18 Years - | Sun Yat-sen University | |
| Neoadjuvant SBRT in Localized Advanced HNSCC | NCT06306846 | Head and Neck S... | SBRT+immunochem... Immunochemother... cetuximab+immun... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | NCT00147901 | B-cell Chronic ... | FCCam | 18 Years - | German CLL Study Group | |
| Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | NCT00366275 | Follicular Lymp... | Immunochemother... | 18 Years - 60 Years | IRCCS Policlinico S. Matteo | |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | NCT00801281 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2 | 18 Years - | Polish Lymphoma Research Group | |
| Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | NCT00366275 | Follicular Lymp... | Immunochemother... | 18 Years - 60 Years | IRCCS Policlinico S. Matteo | |
| Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. | NCT06125262 | Esophageal Squa... Immunotherapy Chemotherapy | - | Guangdong Provincial People's Hospital | ||
| Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | NCT05689671 | Non-Small Cell ... | Atezolizumab Nab paclitaxel Carboplatin Pembrolizumab Cisplatin Carboplatin Pemetrexed | 18 Years - | Charite University, Berlin, Germany | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy | NCT05101759 | Neoplasm, Plasm... Lymphoma | Comprehensive G... | 75 Years - | University Hospital, Toulouse | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
